



---

## Workshop Resources for Attendees

---

### [Parkinson's disease therapy: what lies ahead?](#)

Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, Gerrit Machetanz, Antonia F Demleitner, Emily Feneberg, Maike Hagemeyer, Paul Lingor  
J Neural Transm (Vienna). 2023 Jun;130(6):793-820. doi: 10.1007/s00702-023-02641-6. Epub 2023 May 5. **Free PMC article.**

### [Perspectives of People At-Risk on Parkinson's Prevention Research](#)

Jessi L Keavney, Soania Mathur, Karlin Schroeder, Ray Merrell, Sergio A Castillo-Torres, Virginia Gao, Grace F Crotty, Michael A Schwarzschild, John M Poma  
J Parkinsons Dis. 2024 Mar 14. doi: 10.3233/JPD-230436. Online ahead of print.

### [Session 1: PD Heterogeneity](#)

#### [What Patients Say: Large-Scale Analyses of Replies to the Parkinson's Disease Patient Report of Problems \(PD-PROP\)](#)

Connie Marras, Lakshmi Arbatti, Abhishek Hosamath, Amy Amara, Karen E Anderson, Lana M Chahine, Shirley Eberly, Dan Kinel, Sneha Mantri, Soania Mathur, David Oakes, Jennifer L Purks, David G Standaert, Caroline M Tanner, Daniel Weintraub, Ira Shoulson  
J Parkinsons Dis. 2023;13(5):757-767. doi: 10.3233/JPD-225083. **Free PMC article.**

#### [Parkinson's Disease Subtypes: Critical Appraisal and Recommendations](#)

Tiago A. Mestre, Seyed-Mohammad Fereshtehnejad, Daniela Berg, Nicolaas I. Bohnen, Kathy Dujardin, Roberto Erro, Alberto J. Espay, Glenda Halliday, Jacobus J. van Hilten, Michele T. Hu, Beomseok Jeon, Christine Klein, Albert F.G. Leentjens, Johan Marinus, Brit Mollenhauer, Ronald Postuma, Rajasumi Rajalingam, Mayela Rodriguez-Violante, Tanya Simuni, D. James Surmeier, Daniel Weintraub, Michael P. McDermott, Michael Lawton and Connie Marras  
J Parkinsons Dis. 2021;11(2):395-404. doi: 10.3233/JPD-202472. **Free PMC article.**

#### [Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using \$\alpha\$ -synuclein seed amplification: a cross-sectional study](#)

Andrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, Carly M Farris, Yihua Ma, Paula A Urenia, Hieu Nguyen, Roy N Alcalay, Lana M Chahine, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kalpana Merchant, Brit Mollenhauer, Kathleen L Poston, John Seibyl, Tanya Simuni, Caroline M Tanner, Daniel Weintraub, Aleksandar Videnovic, Seung Ho Choi, Ryan



Kurth, Chelsea Caspell-Garcia, Christopher S Coffey, Mark Frasier, Luis M A Oliveira, Samantha J Hutten, Todd Sherer, Kenneth Marek, Claudio Soto; Parkinson's Progression Markers Initiative *Lancet Neurol.* 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6. **Free PMC article.**

### Session 2: Target Validation

#### [Association of a Common Genetic Variant with Parkinson's Disease is mediated by Microglia](#)

Rebekah G Langston, Alexandra Beilina, Xylena Reed, Alice Kaganovich, Andrew B Singleton, Cornelis Blauwendraat, J Raphael Gibbs, Mark R Cookson

*Sci Transl Med.* 2022 Jul 27;14(655):eabp8869. doi: 10.1126/scitranslmed.abp8869. Epub 2022 Jul 27. **Free PMC article.**

#### [Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease](#)

Sarah Jinn, Cornelis Blauwendraat, Dawn Toolan, Cheryl A Gretzula, Robert E Drolet, Sean Smith, Mike A Nalls, Jacob Marcus, Andrew B Singleton, David J Stone

*Hum Mol Genet.* 2019 Oct 1;28(19):3244-3254. doi: 10.1093/hmg/ddz136. **Free PMC article.**

### Session 3: Appropriate tools to enable therapeutics development

#### [Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis](#)

Michaela E. Johnson, Benjamin Stecher, Viviane Labrie, Lena Brundin, and Patrik Brundin

*Trends Neurosci.* 2019 Jan;42(1):4-13. doi: 10.1016/j.tins.2018.09.007. Epub 2018 Oct 17. **Free PMC article.**

#### [A Conversation with Steven Hyman about animal models for autism research](#)

Kris Dickson

Simons Foundation. 2021.

### Session 4: Biomarker use

#### [Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals](#)

Yuzhe Yang, Yuan Yuan, Guo Zhang, Hao Wang, Ying-Cong Chen, Yingcheng Liu, Christopher G. Tarolli, Daniel Crepeau, Jan Bukartyk, Mithri R. Junna, Aleksandar Videnovic, Terry D. Ellis, Melissa C. Lipford, Ray Dorsey and Dina Katabi

*Nat Med.* 2022 Oct;28(10):2207-2215. doi: 10.1038/s41591-022-01932-x. Epub 2022 Aug 22.

**Free PMC article.**



[Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid](#)

Laura Winchester, Imelda Barber, Michael Lawton, Jessica Ash, Benjamine Liu, Samuel Evetts, Lucinda Hopkins-Jones, Suppalak Lewis, Catherine Bresner, Ana Belen Malpartida, Nigel Williams, Steve Gentlemen, Richard Wade-Martins, Brent Ryan, Alejo Holgado-Nevedo, Michele Hu, Yoav Ben-Shlomo, Donald Grosset, Simon Lovestone

Brain Commun. 2022 Dec 28;5(1):fcac343. doi: 10.1093/braincomms/fcac343. eCollection 2023. **Free PMC article.**

[Session 5: Lessons from PD adjacent communities](#)

[Preclinical target validation for non-addictive therapeutics development for pain](#)

Richard Hargreaves, Karen Akinsanya, Seena K. Ajit, Neel T. Dhruv, Jamie Driscoll, Peter Farina, Narender Gavva, Marie Gill, Andrea Houghton, Smriti Iyengar, Carrie Jones, Annemieke Kavelaars, Ajamete Kaykas, Walter J. Koroshetz, Pascal Laeng, Jennifer M. Laird, Donald C. Lo, Johan Luthman, Gordon Munro, Michael L. Oshinsky, G. Sitta Sittampalam, Sarah A. Woller & Amir P. Tamiz

Expert Opin Ther Targets. 2022 Sep;26(9):811-822. doi: 10.1080/14728222.2022.2147063.

Alzheimer's disease drug development pipeline: 2024 (available 4/24/24 – see [2023 report](#))

Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Feixiong Cheng  
Alzheimers Dement (N Y).

[Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS](#)

Timothy M Miller, Merit E Cudkowicz, Angela Genge, Pamela J Shaw, Gen Sobue, Robert C Bucelli, Adriano Chiò, Philip Van Damme, Albert C Ludolph, Jonathan D Glass, Jinsy A Andrews, Suma Babu, Michael Benatar, Christopher J McDermott, Thos Cochrane, Sowmya Chary, Sheena Chew, Han Zhu, Fan Wu, Ivan Nestorov, Danielle Graham, Peng Sun, Manjit McNeill, Laura Fanning, Toby A Ferguson, Stephanie Fradette; VALOR and OLE Working Group  
N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.

[Session 6: Best practices for advancing development](#)

[Novel targeted therapies for Parkinson's disease](#)

Theodora Ntetsika, Paraskevi-Evita Papatoma, Ioanna Markaki

Mol Med. 2021 Feb 25;27(1):17. doi: 10.1186/s10020-021-00279-2. **Free PMC article.**



[SPARKing academic technologies across the valley of death](#)

Jeewon Sylvia Kim, Stephen Kargotich, Sophia H. Lee, Rieko Yajima, Adriana Ann Garcia, Gretchen Ehrenkauffer, Mary Romeo, Peter Santa Maria, Kevin V. Grimes & Daria Mochly-Rosen  
Nat Biotechnol. 2024 Feb;42(2):339-342. doi: 10.1038/s41587-024-02130-5.

[Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease](#)

Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G. Henry, Jennifer C. Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V. Bondar, Rajarshi Ghosh, Michael T. Maloney, Nicholas E. Propson, Yuda Zhu, Romeo D. Maciucă, Laura Harris, Angela Kay, Peter LeWitt, T. Alex King, Drew Kern, Aaron Ellenbogen, Ira Goodman, Andrew Siderowf, Jason Aldred, Omid Omidvar, Shababa T. Masoud, Sonnet S. Davis, Annie Arguello, Anthony A. Estrada, Javier de Vicente, Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang Nguyen, Kimberly Scarce-Levie, Carole Ho, Matthew D. Troyer

Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8.

[Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson's Disease](#)

Daniel F Tardiff, Matthew Lucas, Iwona Wrona, Belle Chang, Chee Yeun Chung, Bertrand Le Bourdonnec, Kenneth J Rhodes, Robert H Scannevin

Mol Neurobiol. 2022 Apr;59(4):2171-2189. doi: 10.1007/s12035-021-02695-1. Epub 2022 Jan 20. **Free PMC article.**